KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income - Minority (2018 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Net Income - Minority for 8 consecutive years, with -$4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income - Minority rose 42.86% year-over-year to -$4.0 million, compared with a TTM value of -$4.0 million through Dec 2025, up 42.86%, and an annual FY2025 reading of -$4.0 million, up 42.86% over the prior year.
  • Net Income - Minority was -$4.0 million for Q4 2025 at Teva Pharmaceutical Industries, roughly flat from -$4.0 million in the prior quarter.
  • Across five years, Net Income - Minority topped out at -$4.0 million in Q3 2025 and bottomed at -$987.0 million in Q2 2021.
  • Average Net Income - Minority over 5 years is -$557.0 million, with a median of -$656.0 million recorded in 2023.
  • The sharpest move saw Net Income - Minority fell 1.54% in 2021, then skyrocketed 98.87% in 2024.
  • Year by year, Net Income - Minority stood at -$966.0 million in 2021, then rose by 17.81% to -$794.0 million in 2022, then increased by 21.91% to -$620.0 million in 2023, then surged by 98.87% to -$7.0 million in 2024, then soared by 42.86% to -$4.0 million in 2025.
  • Business Quant data shows Net Income - Minority for TEVA at -$4.0 million in Q4 2025, -$4.0 million in Q3 2025, and -$7.0 million in Q1 2025.